OPDIVO (nivolumab) | OPDIVO (nivolumab) + YERVOY (ipilimumab)

BACK

Pricing Information

Like many patients, knowing what you may pay for treatment can be a major concern. That's why Bristol Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP) costs and possible resources that may help make them more affordable.

The information below will help you understand not only the list price of your medication, but what your out-of-pocket (OOP) costs might be based on your infusion schedule and insurance coverage.

Click below to learn more about your medication cost based on your infusion schedule and insurance coverage.

For people prescribed OPDIVO + YERVOY for newly diagnosed Advanced Lung Cancer

For people prescribed OPDIVO + YERVOY for other indications

For most OPDIVO + YERVOY combination indications, there are two phases in the recommended dosing schedule.

PHASE 1

FULL INDICATIONS

MORE IMPORTANT SAFETY INFORMATION

OPDIVO + YERVOY* ranges from $25,677–$46,060 depending on the dose your doctor has prescribed.

PHASE 2

Treatment continues with just OPDIVO alone. For patients receiving OPDIVO 240 mg every 2 weeks, the list price is $7,635 per infusion.† For patients receiving OPDIVO 480 mg every 4 weeks, the list price is $15,269 per infusion period.

The dosing schedule for malignant pleural mesothelioma (MPM) does not follow the 2-phased schedule noted above. For adult patients being treated with OPDIVO + YERVOY newly diagnosed with MPM that cannot be removed by surgery, your doctor may initiate the following treatment schedule: OPDIVO 360 mg every 3 weeks + YERVOY 1 mg/kg every 6 weeks. The list price for OPDIVO 360 mg and YERVOY 1 mg/kg infusion is $28,858.

The information below will help you better understand what you could pay for your medication based on your insurance coverage.

If you have commercial insurance	You could pay as little as $0 per medication with the BMS Oncology Co-pay Assistance Program. Learn about this program
If you have Medicare	Depending on your specific Medicare benefits, you may pay 0-20% of the medication list price. If you have Medicare Part B, you may also have a supplemental insurance plan that may pay all or part of your OPDIVO or OPDIVO + YERVOY cost. If you have Medicare Part C, there is an out-of-pocket total Medical Expense maximum, so what you will pay for your medication will depend on your plan's benefit design and the level of your other healthcare expenses during the year. Please check with your Medicare plan administrator for more details and to understand your specific costs.
If you have Medicaid	You could pay $0-$20 per medication (depending on state plan). To find out if you qualify for Medicaid, or to get more information about co-payments in your state, please use this link to visit the Medicaid website.
If you do not have insurance coverage	If you do not have medical coverage or your insurance does not cover OPDIVO + YERVOY, you can expect to pay the list price shown above. Patients without insurance are encouraged to call 1-855-OPDIVO-1 to explore potential options.

For additional information, the BMS Access Support® program provides resources to help patients understand their insurance coverage and find information on sources of financial support.

As part of the BMS Access Support program, the BMS Oncology Co-Pay Assistance Program may help eligible commercially insured patients pay only $0 per medication. BMS will cover the rest of the cost, up to $25,000 per year per product.

Please visit BMS Access Support or call BMS Access Support at **1-800-861-0048**, 8 AM to 8 PM ET, Monday to Friday.

*The list price and Medicare range for OPDIVO + YERVOY combination therapy is based on the approved induction phase for either advanced renal cell carcinoma (RCC), advanced (metastatic) melanoma, or colorectal cancer (MSI-H/dMMR) and is current as of July 1, 2024. The price for weight-based dosing may vary depending on the patient's weight. For RCC and CRC, the pricing for OPDIVO 3 mg/kg and YERVOY 1 mg/kg is based on an 82.5 kg patient. For metastatic melanoma, the pricing for OPDIVO 1 mg/kg and YERVOY 3 mg/kg is based on an 80 kg patient. For patients being treated with OPDIVO + YERVOY for advanced hepatocellular carcinoma (HCC), your doctor may initiate the following treatment schedule: OPDIVO 1 mg/kg every 3 weeks + YERVOY 3 mg/kg every 3 weeks based on a 66.5 kg patient. After 9 weeks, the treatment schedule may continue as follows: OPDIVO 240 mg every 2 weeks or OPDIVO 480 mg every 4 weeks. This price does not include the cost of administration and other medicines or infusion center costs.

†The list prices are current as of July 1, 2024.

For people prescribed OPDIVO

JHU 2235
Merck Sharp v. Johns Hopkins
IPR2024-00647

BACK